Hong Kong stock market anomaly | Juzi Bio (02367) rose more than 5%, recently received a patent authorization for the invention of type XVII collagen by the restructuring personnel.

Juzi Biotech (02367) rose more than 5%, as of the time of writing, rose 5.17%, reported HKD 37.6, with a turnover of HKD 0.141 billion.

Zhitong FinanceSep 19 02:57 ET

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Largest Shareholder, Chief Scientific Officer Daidi Fan Sees Holdings Value Fall by 8.6% Following Recent Drop

Simply Wall StSep 15 20:32 ET

[Brokerage Focus] Haitong Securities maintains a "outperform the market" rating for Giant Bio (02367) and is bullish on the continuous expansion of growth space in multiple categories, series, and scenarios.

Jinwu News | Haitong Securities issued a research report stating that Juzi Bio (02367) achieved revenue of 2.54 billion yuan in the first half of 2024, a year-on-year increase of 58.2%; net income attributable to shareholders of 0.983 billion yuan, a year-on-year increase of 47.4%, adjusted net profit of 1.027 billion yuan, a year-on-year increase of 51.8%. Diluted EPS is 0.97 yuan. The bank believes that the company's recombined collagen preparation technology has deep barriers, leading industrialization, and broad commercial space. The expansion of functional skincare categories is supported by online direct sales, with dual-drive strengthening collagen protein user mindset and high repurchase rate under the solid brand strength of profit optimization.

金吾財訊Sep 2 04:37 ET

guolian: In the second half of the year, focus on the reorganization of collagen protein track and beauty november 11 shopping festival-related promotions to boost.

At the current time point, analyzing the changes in operation in the first half of 2024, optional consumer categories such as medical beauty and cosmetics are still in the process of recovery.

Zhitong FinanceSep 2 02:42 ET

Statistics on the capital trend of the ChiNext Stock Connect (T+2) | August 23rd.

Capital trend of the Intelligent Hong Kong-Stock Connect|August 23rd

Zhitong FinanceAug 22 19:30 ET

Citigroup reiterates a "buy" rating on Genscript Biotech (02367) with a target price raised to HKD59.5.

Citigroup has revised upward the net income forecast for Genscript Biotech (02367) in the period from 2024 to 2026 by 4.4%, 3.8%, and 3.8%, respectively.

Zhitong FinanceAug 20 23:33 ET